Neurocrine Biosciences Q3 2020 Earnings Report
Key Takeaways
Neurocrine Biosciences announced its Q3 2020 financial results, with INGREZZA net product sales reaching $254 million, a 28% increase year-over-year. The company reported a GAAP net loss of $58 million, or $0.62 per share, and a non-GAAP net income of $96 million, or $0.97 per share. ONGENTYS was launched in the U.S. in late September.
INGREZZA net product sales for Q3 2020 were $254 million, a 28% increase year-over-year.
New prescriptions of INGREZZA increased slightly in Q3 2020 compared to Q2 2020.
ONGENTYS launched in the United States in late September 2020, with net product sales of approximately $0.1 million in Q3 2020.
The company initiated a Phase II study of NBI-827104 for the treatment of Continuous Spikes and Waves During Sleep (CSWS) Epilepsy.
Neurocrine Biosciences
Neurocrine Biosciences
Neurocrine Biosciences Revenue by Segment
Forward Guidance
The company provided full-year 2020 expense guidance.
Positive Outlook
- Combined GAAP R&D and SG&A expenses are expected to be in the range of $880 million to $900 million.
- Combined Non-GAAP R&D and SG&A expenses are expected to be in the range of $590 million to $610 million.